Development of Processes for Recombinant L-Asparaginase II Production by <i>Escherichia coli</i> Bl21 (De3): From Shaker to Bioreactors
Since 1961, L-asparaginase has been used to treat patients with acute lymphocytic leukemia. It rapidly depletes the plasma asparagine and deprives the blood cells of this circulating amino acid, essential for the metabolic cycles of cells. In the search for viable alternatives to produce L-asparagin...
Gorde:
| Egile Nagusiak: | , , , , , |
|---|---|
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
MDPI AG
2020-12-01
|
| Saila: | Pharmaceutics |
| Gaiak: | |
| Sarrera elektronikoa: | https://www.mdpi.com/1999-4923/13/1/14 |
| Etiketak: |
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|